Guggenheim analyst Debjit Chattopadyaya lowered the firm’s price target on Intellia Therapeutics to $64 from $78 and keeps a Buy rating on the shares. Based on recent statistical analyses related to an adjacent ATTR silencing approach, the firm has “moderately” adjusted it estimated odds of success for NTLA-2001 to 60% from 65%, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTLA:
- Intellia Therapeutics reports Q4 EPS ($1.46), consensus ($1.45)
- NTLA Upcoming Earnings Report: What to Expect?
- Intellia Therapeutics price target lowered to $24 from $38 at Baird
- Intellia Therapeutics, ReCode Therapeutics to develop genomic medicines for CF
- Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
